Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis 2 | Clinical Trial - LEVANT 2


The goal of this trial was to assess safety and efficacy of a paclitaxel-coated balloon compared with routine percutaneous transluminal angioplasty (PTA) in patients with femoropopliteal peripheral artery disease (PAD).

Contribution to the Literature: The LEVANT 2 trial shows that PTA with a paclitaxel-based DEB is superior to PTA with a regular balloon for primary patency in patients with short to moderately long femoropopliteal arterial lesions.